Ss-Lar
Gastro-entero-pancreatic Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Gastro-entero-pancreatic Neuroendocrine Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Mayo Clinic | Phase 2/3 | BB |
Irinotecan National Cancer Institute (NCI) | Phase 3 | BB |
Oxodotreotide Vanderbilt-Ingram Cancer Center | Phase 4 | BB |
Octreotide Pamoate National Cancer Institute (NCI) | Phase 3 | BB |
Eloxatin Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2/3 | BB |
View all 44 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →